DUSP1 and metabolic dysfunction-associated steatotic liver disease: At the same time, lncRNA NR_038323 reduced the degree of renal fibrosis by targeting DUSP1, suggesting that DUSP1 is a potential therapeutic target for CKD with NAFLD (29–31).